MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $4.64, for a total value of $13,920.00. Following the completion of the sale, the director now directly owns 141,950 shares in the company, valued at approximately $658,648. The trade was a 2.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

John Joseph Johnston also recently made the following trade(s):

• On Thursday, December 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The shares were sold at an average price of $4.01, for a total transaction of $12,030.00.

MaxCyte Trading Down 0.7 %

NASDAQ:MXCT traded down $0.04 during trading hours on Wednesday, reaching $4.65. 426,831 shares of the company were exchanged, compared to its average volume of 685,661. The stock’s 50-day moving average is $4.20 and its 200-day moving average is $4.08. MaxCyte, Inc. has a twelve month low of $3.16 and a twelve month high of $5.29. The firm has a market cap of $491.02 million, a PE ratio of -13.66 and a beta of 1.29.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The firm had revenue of $8.16 million for the quarter, compared to analyst estimates of $7.50 million. During the same period last year, the company posted ($0.11) EPS. As a group, research analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current year.

Institutional Trading of MaxCyte

A number of institutional investors have recently made changes to their positions in MXCT. Intech Investment Management LLC purchased a new position in shares of MaxCyte in the third quarter worth about $51,000. China Universal Asset Management Co. Ltd. grew its position in shares of MaxCyte by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock valued at $79,000 after purchasing an additional 7,930 shares in the last quarter. Verition Fund Management LLC increased its stake in shares of MaxCyte by 39.5% in the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after acquiring an additional 6,045 shares during the last quarter. Creative Planning increased its position in MaxCyte by 33.6% during the third quarter. Creative Planning now owns 28,652 shares of the company’s stock worth $111,000 after purchasing an additional 7,212 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of MaxCyte by 84.5% during the 3rd quarter. SG Americas Securities LLC now owns 37,969 shares of the company’s stock valued at $148,000 after buying an additional 17,385 shares during the period. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.